Cognasse F, Garraud O
The Rhône-Alpes-Auvergne Regional Branch of the French National Blood System EFS, 42000 Saint-Étienne, France.
EA3064, Faculty of Medicine, University of Lyon, 42023 Saint-Étienne, France; Palliative Care Unit, the Ruffec Hospital, 16700 Ruffec, France; Institut National de la Transfusion Sanguine, 75015 Paris, France.
Transfus Clin Biol. 2019 Sep;26(3):144-146. doi: 10.1016/j.tracli.2019.06.324. Epub 2019 Jul 4.
Platelet transfusion is a safe process, but during or after the process the recipient may experience an adverse reaction and occasionally a serious adverse reaction (SAR). Platelet concentrate transfusion may be liable for significant absence of beneficial response. Danger may manifest clinically or biologically; in the latter case, manifestations are frequently an absence of the expected response to the blood component by the recipient. Blood platelets exert roles in inflammation, especially through the immunomodulator complex CD40/CD40L (sCD40L). In this review, we concentrate on the inflammatory potential of platelets and their participation to SARs in transfusion.
血小板输注是一个安全的过程，但在此过程中或之后，受血者可能会出现不良反应，偶尔还会出现严重不良反应（SAR）。输注浓缩血小板可能会导致明显缺乏有益反应。危险可能在临床上或生物学上表现出来；在后一种情况下，表现通常是受血者对血液成分没有预期的反应。血小板在炎症中发挥作用，特别是通过免疫调节复合物CD40/CD40L（可溶性CD40L）。在这篇综述中，我们重点关注血小板的炎症潜能及其在输血严重不良反应中的作用。
